- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | iSpecimen Inc.: iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks | 435 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ: ISPC) a provider of human biospecimens, recently completed an international cancer research project involving hundreds... ► Artikel lesen | |
| 14.08. | iSpecimen Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| 07.08. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants | 421 | GlobeNewswire (Europe) | WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical... ► Artikel lesen | |
| 07.08. | E.F. Hutton begleitet Kapitalerhöhung von iSpecimen über 5 Mio. US-Dollar | 1 | Investing.com Deutsch | ||
| 07.08. | E.F. Hutton serves as placement agent for iSpecimen $5M offering | 2 | Investing.com | ||
| 07.08. | E.F. Hutton serves as agent for iSpecimen $5M offering | 1 | Investing.com | ||
| 07.08. | E.F. Hutton begleitet 5-Millionen-Dollar-Angebot von iSpecimen | 1 | Investing.com Deutsch | ||
| 06.08. | iSpecimen prices $5M public offering; shares down | 5 | Seeking Alpha | ||
| 06.08. | iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 17.07. | iSpecimen Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 14.07. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.07. | iSpecimen Inc. - S-1/A, General form for registration of securities | 3 | SEC Filings | ||
| 24.06. | iSpecimen Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.05. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.05. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | iSpecimen schließt Privatplatzierung über 2,5 Mio. US-Dollar ab | 12 | Investing.com Deutsch | ||
| 12.05. | iSpecimen raises $2.5M in private placement via E.F. Hutton | 17 | Investing.com | ||
| 11.05. | iSpecimen announces pricing of approximately $2.5M private placement | 8 | Seeking Alpha | ||
| 09.05. | iSpecimen sichert sich 2,5 Mio. US-Dollar durch Privatplatzierung zu 5,12 US-Dollar pro Aktie | 2 | Investing.com Deutsch |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | DAX Verlierer: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| ILLUMINA | 186,64 | +0,27 % | $100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today | ||
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| COSCIENS BIOPHARMA | 4,430 | 0,00 % | COSCIENS Biopharma Inc. Reports Q2 2026 Results | TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) ("COSCIENS" or the "Company") today reported its financial and operating results for the second... ► Artikel lesen | |
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen |
ISPECIMEN INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.